Related Experiment Video
Updated: Apr 5, 2026
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer
Christian Mayr1, Andrej Wagner2, Angelika Stoecklinger3
1Department of Internal Medicine I, Paracelsus Medical University, Salzburg, Austria Laboratory for Tumour Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.
Background/Aim:
Polycomb repressive complex 2 (PRC2), an epigenetic master regulator, contributes to progression and development of biliary tract cancer (BTC). The present study investigated the effects of the PRC2 inhibitor 3-deazaneplanocin A (DZNep) on BTC cell lines.
Materials And Methods:
In vitro effects of DZNep treatment were analyzed for cell viability, gene expression and functional characteristics of cancer stem cell (CSC).
Results:
DZNep treatment caused a cell line- and dose-dependent decrease in viability. In the EGI-1 cell line, a direct cytotoxic effect was accompanied by mRNA down-regulation of the PRC2 core components, cyclins as well as of CSC-related genes. Furthermore, DZNep affected putative CSCs by reduction of sphere formation and aldehyde dehydrogenase-1-positive cells. The stem cell characteristics of these subpopulations were verified by real-time polymerase chain reaction analysis.
Conclusion:
Taken together, our results show that DZNep might be a promising pharmacological agent for future therapies regarding BTC.
Insights
The Polycomb repressive complex 2 (PRC2) inhibitor 3-deazaneplanocin A (DZNep) reduced biliary tract cancer cell viability and key cancer stem cell characteristics, suggesting its therapeutic potential.
Area of Science:
- Epigenetics
- Cancer Biology
- Pharmacology
Background:
- Polycomb repressive complex 2 (PRC2) is an epigenetic regulator implicated in biliary tract cancer (BTC) progression.
- Targeting PRC2 offers a potential therapeutic strategy for BTC.
Purpose of the Study:
- To investigate the effects of the PRC2 inhibitor 3-deazaneplanocin A (DZNep) on BTC cell lines.
- To assess DZNep's impact on cell viability, gene expression, and cancer stem cell (CSC) properties.
Main Methods:
- In vitro analysis of DZNep treatment on BTC cell lines.
- Assessed cell viability, gene expression (PRC2 components, cyclins, CSC markers), sphere formation, and aldehyde dehydrogenase-1 (ALDH1)-positive cells.
- Verified stem cell characteristics using real-time polymerase chain reaction.
Main Results:
- DZNep treatment decreased BTC cell viability in a dose- and cell line-dependent manner.
- Observed downregulation of PRC2 components, cyclins, and CSC-related genes in EGI-1 cells.
- DZNep reduced sphere formation and ALDH1-positive cells, indicating an effect on CSCs.
Conclusions:
- DZNep exhibits cytotoxic effects and reduces CSC characteristics in BTC cells.
- DZNep demonstrates potential as a pharmacological agent for future BTC therapies.
More Related Videos
19:02High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
09:24Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells
Published on: May 9, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...